



TEXAS MEDICAID Clinical Edit Prior Authorization solriamfetol (SUNOSI)

STEP 1: CLEARLY PRINT AND COMPLETE TO EXPEDITE PROCESSING

Date:	Prescriber First & Last Name:
Patient First & Last Name:	Prescriber NPI:
Patient Address:	Prescriber Address:
Patient ID:	Prescriber Phone:
Patient Date of Birth:	Prescriber Fax:

STEP 2: MEDICATION INFORMATION

Medication Requested (Name):	Quantity Requested:
Dose Requested:	Dosing Instructions:

Patient's Primary Diagnosis: _____ ICD 10 Code: _____

Please indicate ONE (1) of the following:
 STAR / STAR KIDS client (**Go to Step 3 - PDL PA Criteria Applies**)
OR CHIP / PERINATE client (**Go to Step 4**)

STEP 3: PDL PRIOR AUTHORIZATION CRITERIA FOR NON-PREFERRED PRODUCT

- Has the client failed a 30-day treatment trial with at least one (1) preferred agent in the last 180 days?
 Yes (Go to Step 4 Question 1) No (Go to #2)
- Is there documented allergy or contraindication to preferred agents in this class?
 Yes (Go to Step 4 Question 1) No (Go to #3)
- Is the drug necessary for treatment of stage-4 advanced metastatic cancer and associated conditions?
 Yes (Go to Step 4 Question 1) No (Deny)



STEP 4: CLINICAL PRIOR AUTHORIZATION CRITERIA

- 1. Is the client greater than or equal to (\geq) 18 years of age?
 Yes (Go to #2) No (Deny)
- 2. Does the client have a diagnosis of narcolepsy in the last 730 days?
 Yes (Go to #5) No (Go to #3)
- 3. Does the client have a diagnosis of obstructive sleep apnea in the last 730 days?
 Yes (Go to #4) No (Deny)
- 4. Does the client have a procedure code for continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP) in the last 730 days?
 Yes (Go to #5) No (Deny)
- 5. Does the client have at least 30 days therapy of modafinil (PROVIGIL) or armodafinil (NUVIGIL) in the last 365 days?
 Yes (Go to #6) No (Deny)
- 6. Does the client have a claim for a monoamine oxidase (MAO) inhibitor in the last 90 days?
Examples of MAO inhibitors include linezolid (ZYVOX), MARPLAN, phenelzine (NARDIL), rasagiline (AZILECT), selegiline (EMSAM, ZELAPAR), and tranylcypromine (PARNATE).
 Yes (Deny) No (Go to #7)
- 7. Does the client have a diagnosis of end stage renal disease (ESRD) or dialysis in the last 365 days?
 Yes (Deny) No (Go to #8)
- 8. Is the daily dose less than or equal to (\leq) 1 tablet daily?
 Yes (Approve – 365 days) No (Deny)

STEP 5: SIGN AND FAX TO: NAVITUS PRIOR AUTHORIZATION AT: 855-668-8553

Prescriber Signature: _____ **Date:** _____

If criteria not met, submit chart documentation with form citing complex medical circumstances.
For questions, please call Navitus Customer Care at 1-877-908-6023.